SCWorx Corp. (WORX): BCG Matrix [Dec-2025 Updated]

You're looking at SCWorx Corp. (WORX) in late 2025, and honestly, the public data makes a clean read defintely tough, so we're mapping their portfolio based on their last known pivot and historical segments. Here's the quick math: the firm is clearly leaning on its legacy maintenance contracts as the Cash Cow funding source, while its future hinges on high-risk, high-capital Question Marks like new AI modules, all while trying to shed the low-growth drag of its past Dogs in the PPE space; a true Star remains conspicuously absent. To see precisely where your capital is exposed-from the stable foundation to the unproven growth engines-dive into the full BCG breakdown below.

Background of SCWorx Corp. (WORX)

You're looking at SCWorx Corp. (WORX) as of late 2025, and honestly, the story is one of a company fighting for compliance while trying to grow its core healthcare data business. SCWorx Corp. is fundamentally a provider of data content and services specifically for the healthcare industry. They focus on the repair, normalization, and interoperability of information for healthcare providers, plus they offer big data analytics for that sector.

Operationally, they sell an advanced software solution designed to manage healthcare providers' foundational business applications. The company has been actively working to expand its network, announcing a new collaboration in August 2025 and securing a significant contract renewal in October 2025. That renewal, a new three-year term with an existing partner, is valued at approximately $1,692,000, representing a 113% increase over the prior agreement.

Financially, things are tight, which is typical for a company this size. For the quarter ending September 30, 2025, SCWorx Corp. reported revenue of $705.80K, bringing the trailing twelve months (TTM) revenue to $2.78M. Looking at the first half of 2025, the three months ended June 30, 2025, showed revenue of $682,632 and a loss from operations of $(307,147). The overall picture shows a negative net profit margin of -139.71% and an EBIT margin of -40.7%, indicating they are still struggling to turn sales into net income.

The stock market situation adds another layer of complexity. As of late 2025, SCWorx Corp. has a market capitalization around US$3.95m. Critically, the company received a 180-day extension from Nasdaq on October 14, 2025, to get its common stock price back above the $1.00 minimum bid requirement, with a new deadline set for April 6, 2026. They are definitely monitoring that share price, and they've previously approved a reverse stock split if needed. Anyway, they aren't paying dividends; all focus is on operational improvement and growth initiatives.

Finance: draft 13-week cash view by Friday.

SCWorx Corp. (WORX) - BCG Matrix: Stars

No clear Star product line is evident in recent public filings; SCWorx Corp.s focus remains on stabilizing core operations.

The financial data from the period ending September 30, 2025, shows a trailing twelve-month revenue of $2.78 million, with a net loss of $2,382,388 for the six months ended around that date. Cash on the balance sheet was reported at $340,209. Management disclosed substantial doubt about the company's ability to continue as a going concern within one year, a situation that requires significant cash burn management rather than investment in high-growth areas. The company also received a 180-day extension from Nasdaq to meet the minimum bid price requirement, with compliance needed by April 6, 2026, by closing at or above $1.00 per share for 10 consecutive business days.

A true Star would require a high-growth, high-market-share product, which SCWorx Corp. has not demonstrated in the volatile healthcare IT space. The company's year-over-year revenue growth as of Q4 2025 was -13.64%, significantly underperforming the US Health Information Services industry revenue growth rate of 17.8% for the same period. This comparison illustrates the market share challenge.

Any new, successful Software as a Service (SaaS) module would quickly transition from a Question Mark to a Star, but that has not materialized yet. The current offerings are centered on data management and analytics within healthcare, which are areas with potential growth, but current execution does not reflect Star status.

• Virtualized Item Master File repair and automation.
• Charge Description Master (CDM) management.
• Contract management and RFP automation.
• Big data analytics modeling and data warehousing.

One recent contract renewal, however, shows success in securing existing business, with an agreement valued at approximately $1,692,000, representing a 113% increase in contract value over three years.

SCWorx Corp. (WORX) - BCG Matrix: Cash Cows

You're looking at the core, established revenue streams for SCWorx Corp. (WORX), the segment that, by definition, should be funding the rest of the operation. These are the legacy healthcare supply chain software maintenance and support contracts.

These contracts provide a stable, recurring revenue base, even if the growth rate is near zero. The fact that SCWorx Corp. renewed a significant agreement with an existing healthcare partner, boosting that contract's value by 113% to approximately $1,692,000, shows a deep, sticky relationship with a core user base, which is the hallmark of a high market share in a mature niche. This partner has collaborated with SCWorx Corp. for eight years.

The core software platform, despite low market growth-the broader Healthcare Supply Chain Management Market is projected to grow at an 11.02% CAGR through 2030-generates positive cash flow with minimal reinvestment needs. We see the recurring nature in the deferred revenue balance, which was $219,250 as of June 30, 2025.

This segment is the primary source of operational funding for other, riskier ventures. Here's a look at the revenue flow for the most recent comparable quarters, which illustrates the mature, stable nature of this revenue base:

The slight year-over-year dip in revenue for the three months ended June 30, 2025, compared to the same period in 2024, suggests the market for this specific legacy platform is mature, aligning with the low growth characteristic of a Cash Cow. Still, the renewal mentioned above indicates a strong hold on key accounts.

The cash flow characteristics, though masked by overall company losses, are defined by the nature of these contracts:

• Legacy platform requires low feature development.
• Support infrastructure is largely amortized.
• Revenue is recognized ratably over the contract term.
• Remaining Performance Obligations as of June 30, 2025, totaled $219,250.
• The company aims to generate positive operating cash flows by the end of 2025.

For SCWorx Corp., these contracts represent the established business unit that, when performing optimally, should provide the necessary capital base. You want to maintain this position without overspending on promotion.

Finance: draft 13-week cash view by Friday.

SCWorx Corp. (WORX) - BCG Matrix: Dogs

You're looking at the segment of SCWorx Corp. (WORX) that is clearly struggling to generate meaningful returns, the Dogs quadrant. This is where the volatile, low-margin sales of Personal Protective Equipment (PPE) and COVID-19 related products sit right now.

The latest snapshot from the third quarter ended September 30, 2025, shows the pressure. Quarterly revenue for this period was reported at $705.799K, which represented a 7.10% decrease over sales of $759.724K in the same period last year. Honestly, this trend of declining top-line contribution from this area signals a market that has moved on from the pandemic-driven demand spikes.

This segment has seen a significant market decline post-pandemic, resulting in low growth and low market share. The overall company performance reflects this drag; the trailing Earnings Per Share (EPS) as of November 12, 2025, stood at -$0.95, and the EBITDA for the latest reported period showed a negative -$1.15 M USD with a corresponding EBITDA margin of -42.13%. High inventory risk and obsolescence costs are likely draining capital from the core business, even if the latest reported Inventory-to-Revenue ratio for the quarter ended September 30, 2025, was 0.00.

Here's a quick look at the hard numbers reflecting this unit's poor financial profile as of late 2025:

When you see a unit with this profile, the strategic path is usually clear. Expensive turn-around plans usually do not help, so you need decisive action. Divestiture or complete wind-down of this non-core, low-return business is a clear action item for SCWorx Corp. (WORX) management.

The characteristics defining this Dog segment include:

• Low market share in a shrinking post-pandemic market.
• Negative operating margins, evidenced by the -42.13% EBITDA margin.
• Capital tied up in potentially obsolete inventory assets.
• Stock price trading near its 52-week low of $0.2260 USD (reached November 20, 2025).
• Negative cash flow impact from operations.

Finance: draft the divestiture impact analysis for the PPE unit by next Wednesday.

SCWorx Corp. (WORX) - BCG Matrix: Question Marks

You're looking at the new, unproven software modules or services SCWorx Corp. is pushing, which fit squarely into the Question Marks quadrant. These are the ventures aimed at emerging healthcare IT needs, specifically the big data analytics solutions they market to improve information flow within hospitals. These initiatives represent the company's attempt to pivot into higher-growth areas beyond their core data repair and normalization services. Honestly, these are the bets that could define the next five years for SCWorx Corp.

These ventures operate in markets that theoretically offer high growth, but right now, SCWorx Corp. holds a very small, unverified market share in them. The financial reality for the overall business as of late 2025 shows significant strain, which underscores the risk here. For the nine months ended September 30, 2025, sales were only USD 2.11 million, down from USD 2.31 million a year ago, and the net loss ballooned to USD 3.69 million compared to USD 0.940935 million in the prior year period. The Q3 2025 sales figure itself was USD 0.705799 million, a drop from USD 0.759724 million year-over-year. These new platforms are consuming cash while the established business is contracting.

These Question Marks require significant capital investment for development and marketing without any guaranteed returns, which is why they drain cash. The company raised $1,500,000 in a financing transaction in January 2025, but by June 30, 2025, the cash on the balance sheet was down to $340,209. This cash burn is what you have to fund these new, high-potential areas with. The success of any new platform will determine the company's long-term viability; it's a high-risk, high-reward bet, especially given the reported accumulated deficit of $33,358,454 as of mid-2025.

Here's the quick math on how recent financing relates to the cash position reported in their mid-year filing:

The strategy here is clear: SCWorx Corp. must get markets to adopt these new offerings quickly, or they risk them becoming Dogs when the high-growth market potential fails to materialize. Management has stated an aim to generate positive operating cash flows by the end of 2025 through increased revenue from new customer acquisitions, which directly ties to the success of these Question Marks. The path forward involves heavy investment to gain market share, or a tough decision to divest if the platform proves too slow to gain traction.

The key areas demanding immediate investment focus are:

• Expanding the sales force to push new products.
• Accelerating product offerings development.
• Enhancing project capabilities for implementation.